New Quartesian Agreement with Medidata Expands Sponsor Access to the Medidata Clinical Cloud® during Clinical Trials
December 13 2017 - 8:43AM
Business Wire
Quartesian Signs Enterprise License Agreement
to Offer Complete Access Across Markets to Medidata’s Industry
Leading Cloud Platform
Medidata (NASDAQ:MDSO), the leading global provider of
cloud-based solutions and data analytics for clinical research,
announced that Quartesian, a leading data clinical research
organization (CRO), has signed a new enterprise license agreement
to provide sponsors with complete access to the unified Medidata
Clinical Cloud® and advanced analytics platform. Quartesian has
been a Medidata partner since 2014, with the collaboration
facilitating clinical trial breakthroughs for all market segments,
from small phase I to large phase III studies.
Known for delivering “Clinical Data Your Way” for early and
late-stage clinical studies, Quartesian will build on its expertise
around Medidata Rave®, the world’s leading solution for capturing,
managing and reporting patient data, to now offer a broader set of
data capture and data management capabilities to all of its
customers.
The company completed training and has accreditations to
implement and market Medidata products; including Rave, Medidata
Coder®, Medidata TSDV, Medidata Balance®, which unifies
randomization, trial supply management and EDC into one system and
Medidata Patient Cloud ePRO, a mobile app for patient reported
outcomes. Over the last three years, Quartesian has seen a
significant increase in the demand for these solutions. With its
growing expertise in key Medidata technology for clinical research,
Quartesian is consistently able to rapidly deploy high quality,
cost-efficient clinical data services for many of its life sciences
customers and CRO partners.
"Signing this enterprise agreement has been the culmination of
over three years of experience and partnering with Medidata. We are
excited about being able to offer the complete Medidata suite
across all Quartesian’s market segments. Whether it is phase I or
generic programs or larger phase II and III studies, Quartesian can
offer the industry’s leading data capture system combined with our
low-cost EDC build, data management and biostatistical
programming," said Stephen Boccardo, Quartesian’s senior vice
president of business development and commercial strategy. "This
marks a major milestone in the evolution of Quartesian and cements
our position as the leading provider of high quality, timely
clinical data services delivered with the best value in the
industry. "
“We are delighted that Quartesian is benefitting from Medidata’s
unified platform and advanced analytics,” said Glen de Vries,
Medidata president and co-founder. “We share Quartesian’s mission
of helping life sciences companies advance their scientific goals.
It’s exciting to provide them with tools and data insights that
help achieve it, ultimately accelerating the delivery of new
therapies to patients.”
About Medidata
Medidata is reinventing global drug and medical device
development by creating the industry's leading cloud-based
solutions for clinical research. Through our advanced applications
and intelligent data analytics, Medidata helps advance the
scientific goals of life sciences customers worldwide, including
over 950 global pharmaceutical companies, biotech, diagnostic and
device firms, leading academic medical centers, and contract
research organizations.
The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled
clinical trial data assets provide deep insights that pave the way
for future growth. The Medidata Clinical Cloud is the primary
technology solution powering clinical trials for 18 of the world's
top 25 global pharmaceutical companies and is used by 18 of the top
25 medical device developers—from study design and planning through
execution, management and reporting.
About Quartesian
Quartesian LLC was formed in January 2003 and is headquartered
in Princeton, N.J. with the goal of providing “Clinical Data Your
Way” to its clients. This goal is accomplished by providing
clinical data services faster, more efficient and cost-effective
than ever thought possible. The founding members of Quartesian rely
not only on their technical expertise, but also on their experience
as past clients of clinical service providers. Quartesian prides
itself on its flexibility, responsiveness, adherence to client
specifications and timelines for all projects conducted anywhere in
the world. We have worked with over 100+ pharmaceutical,
biotechnology, generic, and medical device companies with 100%
repeat business track record and no change orders. Learn more about
Quartesian at www.quartesian.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171213005581/en/
MedidataInvestor:Betsy Frank, +1
917-522-4620bfrank@mdsol.comorAnthony D’Amico, +1
732-767-4331adamico@mdsol.comorMedia:Erik Snider, +1
646-362-2997esnider@mdsol.comorQuartesianMedia:Stephen
Boccardo, +609-454-3312Sr. VP Business Development and Commercial
Strategystephen.boccardo@quartesian.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2024 to May 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From May 2023 to May 2024